Alector, Inc. develops clinical-stage biotechnology programs for neurodegenerative diseases, using genetics, immunology and neuroscience to pursue therapies that remove toxic proteins, replace missing proteins and restore immune and nerve cell function. News about ALEC commonly covers the Alector Brain Carrier (ABC) blood-brain barrier platform and ABC-enabled programs across antibodies, enzymes and siRNA.
Company updates focus on Alzheimer’s disease, Parkinson’s disease, Lewy body dementia, frontotemporal dementia and other tauopathies, including candidates such as AL137, AL050 and AL064/AL164, as well as prior clinical programs including nivisnebart and latozinemab. Recurring announcements also include financial results, cash runway commentary, clinical trial results or discontinuations, research pipeline progress, investor conference participation and executive leadership changes.
Alector (Nasdaq: ALEC) announced that management will participate in a fireside chat at the Bank of America CNS Therapeutics Conference on Monday, December 8, 2025 at 2:25 pm ET. A live webcast will be available on the company’s Investors > Events & Presentations page at http://investors.alector.com. A replay will be posted on the Alector website and will remain available for 90 days following the event.
Alector (Nasdaq: ALEC) reported Q3 2025 results and a business update highlighting advancement of its Alector Brain Carrier (ABC) platform and multiple IND‑enabling programs. Cash, cash equivalents, and investments were $291.1 million as of September 30, 2025, providing runway through 2027. Lead ABC candidates AL137 (anti‑amyloid beta) and AL050 (GCase ERT) are advancing toward IND‑enabling studies with IND targets in 2026 and 2027. PROGRESS‑AD Phase 2 interim analysis for nivisnebart (AL101) is planned for 1H 2026. The company reported Q3 collaboration revenue of $3.3M, R&D expense of $29.4M, G&A of $11.5M, and net loss of $34.7M. Latozinemab Phase 3 INFRONT‑3 did not show clinical benefit and related studies will be discontinued.
Alector (Nasdaq: ALEC) reported topline Phase 3 INFRONT-3 results for latozinemab (AL001) in FTD-GRN on Oct 21, 2025: the trial did not meet its clinical co-primary endpoint (CDR plus NACC FTLD-SB) at 96 weeks although it achieved a statistically significant effect on the biomarker co-primary of plasma progranulin (PGRN).
Secondary/exploratory endpoints including fluid biomarkers and vMRI showed no treatment-related effects. The open-label extension and continuation study will be discontinued. Preliminary safety data show no major safety signals. Alector is cutting ~49% of its workforce, expects ~$291.1M cash as of Sep 30, 2025 providing runway through 2027, and plans IND submissions for ABC-enabled AL137 (2026) and AL050 (2027).
Alector (Nasdaq: ALEC) announced a virtual R&D event scheduled for September 22, 2025, focusing on their progranulin (PGRN) franchise and Alector Brain Carrier (ABC) programs. The presentation will highlight two key clinical programs: latozinemab, in Phase 3 trials for frontotemporal dementia, and AL101, in Phase 2 trials for early Alzheimer's disease.
The event will also showcase preclinical data from their ABC-enabled programs, including a brain-penetrant anti-amyloid beta antibody for Alzheimer's and a GCase-enzyme replacement therapy for Parkinson's disease. Additionally, updates on ABC-enabled siRNA programs will be presented, demonstrating the platform's versatility in treating neurodegenerative diseases.
Alector (NASDAQ: ALEC), a late-stage clinical biotechnology company specializing in neurodegeneration therapies, has announced its participation in three upcoming healthcare investor conferences in September 2025.
The company will present at the Cantor Global Healthcare Conference on September 4 at 3:55 p.m. ET, the Morgan Stanley Global Healthcare Conference on September 8 at 10:00 a.m. ET, and the H.C. Wainwright Global Investment Conference on September 9 at 1:30 p.m. ET. All presentations will be available via webcast on Alector's investor relations website, with replays accessible for 90 days.
Alector (NASDAQ:ALEC), a late-stage clinical biotech company, reported Q2 2025 financial results and business updates. The company maintains a strong financial position with $307.3 million in cash, providing runway into H2 2027. Key highlights include the upcoming topline data from the INFRONT-3 Phase 3 trial of latozinemab for FTD-GRN expected by mid-Q4 2025, with potential BLA submissions in 2026.
Q2 2025 financial results showed collaboration revenue of $7.9 million (down from $15.1M in Q2 2024), R&D expenses of $27.6 million (down from $46.3M), and a net loss of $30.5 million. The company updated its 2025 guidance, projecting collaboration revenue between $13-18 million, R&D expenses of $130-140 million, and G&A expenses of $55-65 million.
The company continues advancing its pipeline, including the Phase 2 PROGRESS-AD trial of AL101 in early Alzheimer's disease and development of brain-penetrant candidates through its proprietary Alector Brain Carrier platform.
Alector (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on neurodegeneration therapies, will host its Q2 2025 earnings conference call on Thursday, August 7, 2025, at 4:30 p.m. ET.
The call will feature Dr. Ryan Darby, Associate Professor of Neurology and Director of the Frontotemporal Dementia Clinic at Vanderbilt University Medical Center, who will discuss unmet needs in frontotemporal dementia. The company will release its Q2 2025 financial results before the call.
Participants can access the webcast through Alector's investor relations website, with a 30-day replay available afterward. Phone participants must register online to receive dial-in details.